SEC F	orm 4
-------	-------

 \square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average b	ourden

hours per response:	0.5
Estimated average burden	

	ss of Reporting Perso	on*	2. Issuer Name and Ticker or Trading Symbol <u>Y-mAbs Therapeutics, Inc.</u> [YMAB]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
weden-wede	<u>IISDOLG JOHAH</u>		iii	X	Director	Х	10% Owner		
Wedell-Wedellsborg Johan (Last) (First) (Middle) C/O WECO GROUP A/S RUNGSTED STRANDVEJ 113					Officer (give title		Other (specify		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)		below)		below)		
C/O WECO GR	OUP A/S		07/15/2019						
RUNGSTED ST	FRANDVEJ 113								
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) RUNGSTED				X	Form filed by One	Report	ting Person		
KYST	G7	2960			Form filed by More Person	One Reporting			
(City)	(State)	(Zip)							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities / Disposed Of (5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	07/15/2019		J		860,105	D	(1)	832,391	I	By Weco Group A/S ⁽²⁾
Common Stock								5,010,000	Ι	By WG Biotech ApS ⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Nu of Deriv Secu Acqu (A) of Dispo of (D) (Instr and 5	ative rities ired osed . 3, 4	6. Date Exerc Expiration Da (Month/Day/Y	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Weco Group A/S transferred (a) 540,105 shares of the Common Stock of Y-mAbs Therapeutics, Inc. (the "Company") to shareholders of WG Biotech ApS in exchange for 10,781 ordinary shares of WG Biotech ApS; and (b) 320,000 shares of the Company's Common Stock to shareholders of Weco Biotech ApS in exchange for 20,000 shares of Weco Biotech ApS. The closing sale price of the Company's Common Stock on July 15, 2019, the date of the transaction, was \$22.95.

2. Reporting Person is the majority owner of Weco Group A/S and as such has sole voting and dispositive power with respect to such shares.

3. Reporting Person is the majority owner of WG Biotech ApS and as such has sole voting and dispositive power with respect to such shares.

<u>/s/ Johan Wedell-Wedellsborg</u> 07/17/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.